Advertisement
Advertisement
INCY
Incyte Genomics Inc
120.61
USDSponsored
-1.28
-1.05%
Nov 10, 15:52 UTC -5
Open
Incyte Genomics Inc (INCY) Earnings
INCY Earnings Reports
Positive Surprise Ratio
INCY beat 23 of 43 last estimates.
53%
Next Report
Date of Next Report
Feb 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.58B
/$2.03
Implied change from Q3 26 (Revenue/ EPS)
+1.60%
/-156.39%
Implied change from Q4 25 (Revenue/ EPS)
+5.00%
/+12.78%
Incyte Genomics Inc earnings per share and revenue
On Oct 29, 2026, INCY reported earnings of -3.60 USD per share (EPS) for Q3 26, beating the estimate of -3.92 USD, resulting in a 8.33% surprise. Revenue reached 1.56 billion, compared to an expected 1.49 billion, with a 4.18% difference. The market reacted with a -0.06% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 2.03 USD, with revenue projected to reach 1.58 billion USD, implying an decrease of -156.39% EPS, and increase of 1.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Incyte Genomics Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Incyte Genomics Inc reported EPS of -$3.60, beating estimates by 8.33%, and revenue of $1.56B, 4.18% above expectations.
How did the market react to Incyte Genomics Inc's Q3 2026 earnings?
The stock price moved down -0.06%, changed from $116.87 before the earnings release to $116.80 the day after.
When is Incyte Genomics Inc expected to report next?
The next earning report is scheduled for Feb 08, 2027.
What are the forecasts for Incyte Genomics Inc's next earnings report?
Based on --
analysts, Incyte Genomics Inc is expected to report EPS of $2.03 and revenue of $1.58B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.